Viatris (VTRS): Should You Buy, Sell, or Hold After Q4 Results?
Viatris Stock: Recent Surge and Investor Considerations
Over the past half-year, Viatris shares have outperformed the S&P 500 by 34.7%, climbing to $14.11—a 37.8% increase. This strong performance, fueled in part by robust quarterly earnings, may leave investors questioning their next move.
Should you consider adding Viatris to your portfolio now, or is caution warranted?
Why We’re Not Bullish on Viatris
While recent gains have benefited shareholders, we remain skeptical about Viatris’s long-term prospects. Below are three reasons we’re steering clear of VTRS, along with a stock we prefer.
1. Weak Long-Term Revenue Expansion
Consistent revenue growth is a hallmark of high-quality companies. Although any business can post strong results for a few quarters, sustained expansion over years is what sets leaders apart. Unfortunately, Viatris’s revenue has only grown at a modest 3.7% compound annual rate over the past five years—falling short of our expectations for healthcare stocks.
2. Declining Earnings Per Share
We closely monitor long-term trends in earnings per share (EPS) to assess whether a company’s growth is translating into profitability.
For Viatris, EPS has dropped by an average of 9.8% per year over the last five years, despite revenue growth. This indicates that the company’s profitability per share has eroded as it expanded.
3. Unprofitable Growth Initiatives
Growth is only valuable if it’s efficient. Return on invested capital (ROIC) measures how well a company turns its financing into operating profit.
Viatris’s average ROIC over the past five years was negative 2.6%, meaning the company lost money while attempting to grow. This performance ranks among the weakest in the healthcare industry.
Our Verdict
We appreciate companies that contribute to better health outcomes, but Viatris doesn’t make our list. Although the stock currently trades at a seemingly attractive 5.8× forward P/E (or $14.11 per share), its shaky fundamentals suggest significant downside risk. We believe there are stronger opportunities elsewhere. For example, consider the leading endpoint security platform as a better alternative.
Better Alternatives to Viatris
Don’t Miss: Top 5 Momentum Stocks — The ideal moment to own a standout stock is when the market starts to recognize its potential. These companies aren’t just fundamentally strong; they’re also experiencing significant momentum right now. When strong fundamentals align with short-term catalysts, the opportunity is compelling.
Discover which stocks our AI platform is highlighting this week. Check out the current list of Strong Momentum stocks—completely free.
Our selections feature well-known names like Nvidia (up 1,326% from June 2020 to June 2025) as well as lesser-known companies such as Exlservice, which delivered a 354% five-year return. Find your next winning stock with StockStory today.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Leveraged Bets Drop as Bitcoin Futures Signal Potential Market Shift
GEE Group Inc. (JOB) Surges 35% After Hours: Here's What You Should Know

North Korean Hackers Exploit Dev Device, Steal Millions in Crypto
Bitcoin steady above $70,000 as IEA proposes largest-ever oil reserve release

